We are live on ! Find out more
CCM

Cutter Capital Management Portfolio holdings

AUM $230M
1-Year Est. Return 11.53%
This Fund
S&P 500
This Quarter Est. Return
+1.97%
1 Year Est. Return
+11.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$331M
AUM Growth
+$69.8M
Cap. Flow
+$69.3M
Cap. Flow %
20.92%
Top 10 Hldgs %
55.35%
Holding
39
New
13
Increased
9
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.6M
2
AMGN icon
Amgen
AMGN
+$18.9M
3
KVUE icon
Kenvue
KVUE
+$18.6M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$15.6M
5
CYTK icon
Cytokinetics
CYTK
+$14.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$24.2M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$15.7M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$12.2M
4
HALO icon
Halozyme
HALO
+$10.4M
5
EXEL icon
Exelixis
EXEL
+$9.46M

Sector Composition

Rank Sector Weight
1 Healthcare 93.78%
2 Consumer Staples 5.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
CALL
Sarepta Therapeutics
SRPT
$1.57B
$3.16M 0.95%
+20,000
New +$2.57M
PRGO icon
27
Perrigo
PRGO
$1.4B
$2.57M 0.78%
100,000
-222,114
-69% -$6.53M
ACAD icon
28
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-658,409
Closed -$12.2M
AGIO icon
29
Agios Pharmaceuticals
AGIO
$1.79B
– –
-288,580
Closed -$8.44M
BMY icon
30
Bristol-Myers Squibb
BMY
$133B
– –
-446,900
Closed -$24.2M
CABA icon
31
Cabaletta Bio
CABA
$437M
– –
-157,964
Closed -$2.69M
EXEL icon
32
Exelixis
EXEL
$13.3B
– –
-398,762
Closed -$9.46M
HALO icon
33
Halozyme
HALO
$9.79B
– –
-255,049
Closed -$10.4M
IRWD icon
34
CALL
Ironwood Pharmaceuticals
IRWD
$696M
– –
-250,000
Closed -$2.18M
LLY icon
35
Eli Lilly
LLY
$1.02T
– –
-11,040
Closed -$8.59M
PLRX icon
36
Pliant Therapeutics
PLRX
$64.4M
– –
-194,119
Closed -$2.89M
REGN icon
37
Regeneron Pharmaceuticals
REGN
$78.5B
– –
-16,360
Closed -$15.7M
VRDN icon
38
Viridian Therapeutics
VRDN
$2.09B
– –
-278,638
Closed -$4.88M
KYTX icon
39
Kyverna Therapeutics
KYTX
$444M
– –
-166,514
Closed -$4.14M
1
2

Similar funds

SAM
Selway Asset Management $242M AUM 7.7% 1-Year Est. Return
CW
Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return
IAM
Impact Asset Management Vienna $255M AUM
BCM
BluePointe Capital Management Menlo Park, California $262M AUM 9.24% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
LA
Lane & Associates Moorestown, New Jersey $186M AUM 5.34% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

Cutter Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Cutter Capital Management held 39 positions worth $331M, up 27% from $262M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Cutter Capital Management deployed $69.3M of net new capital in Q2 2024, opening 13 new positions and adding to 9 existing holdings. Its largest new stake was Merck: 175,600 shares worth $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 99% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Perrigo, an estimated $6.53M trimmed.

  • Cutter Capital Management's largest Q2 2024 buy was Merck: 175,600 shares worth $21.7M.
  • Cutter Capital Management added most to Legend Biotech in Q2 2024, an estimated $12.1M increase.
  • Cutter Capital Management's biggest Q2 2024 reduction was Perrigo, cutting an estimated $6.53M.
  • Cutter Capital Management fully exited Bristol-Myers Squibb in Q2 2024, selling an estimated $24.2M.
  • Cutter Capital Management's ten largest holdings make up 55% of its $331M portfolio in Q2 2024.
  • Cutter Capital Management opened 13 new positions and closed 12 in Q2 2024.
  • Cutter Capital Management's portfolio value rose 27% quarter-over-quarter to $331M.

Based on Cutter Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.